Multiple Cholecystokinin Receptors in the CNSColin T. Dourish This volume summarizes the most recent research on CCK, and has contributions from the leading experts in the field. Prominence is given to important advances made using novel CCK receptor antagonists, which have been valuable research tools and may prove to be useful therapies. |
Contents
Introduction | 3 |
Dale Frankenfield | 6 |
Merck Sharp Dohme Research Laboratories West Point PA 19486 | 24 |
Copyright | |
50 other sections not shown
Common terms and phrases
action of CCK activity administration afferent affinity agonist analogues antagonism antagonist devazepide anxiolytic behaviour benzodiazepines binding sites Brain Res caerulein CCK antagonists CCK mRNA CCK receptors CCK-8US CCK-LI CCKA CCKB cells cent central Chapter cholecystokinin antagonist cholecystokinin receptor compounds concentrations cortex Crawley decrease devazepide dopamine doses of CCK Dourish drug effect of CCK endogenous CCK exogenous feeding food intake Freidinger gastric emptying Gibbs guinea pig hippocampus Hökfelt hypothalamus immunoreactivity increase induced inhibition inhibitory injection of CCK interaction labelled Lindén lorglumide Lotti McHugh meal mediated mg/kg Moran morphine morphine analgesia mRNA Natl Acad neurons neuropeptide Neurosci non-peptide nucleus accumbens octapeptide opioid analgesia opioid receptors oxytocin pancreas panic disorder pentagastrin peptide peripheral Pharmacol pharmacological Physiol physiological plasma produced proglumide rat brain receptor antagonist Rehfeld release response role satiating effect satiety selective CCK spinal cord stimulation studies substantia nigra tion vagal vagotomy Vanderhaeghen volume µg/kg